News

Algorithm Sciences, which is developing PulmoProst to treat pulmonary arterial hypertension (PAH), has acquired all assets of Flownix Medical, including the Prometra II pump that would deliver the potential therapy. PulmoProst is an infusion formulation of iloprost, a synthetic version of naturally occurring prostacyclin, a substance that…

Liquidia has licensed the rights in North America to L606, a novel inhaled formulation of treprostinil that’s being tested in trials of people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). “L606 is the perfect life-cycle complement to our pipeline and…

Janssen Pharmaceuticals has submitted an application in Europe asking regulatory authorities to approve the company’s combination therapy of macitentan and tadalafil — developed as a single tablet — for pulmonary arterial hypertension (PAH). The filing comes less than a month after Janssen submitted a similar application seeking approval…

Pregnant women with mild pulmonary hypertension (PH) show a significantly lower risk of maternal and fetal complications than those with moderate-to-severe PH, according to a study from China. “For patients with mild pulmonary hypertension and good cardiac function, continued pregnancy or even delivery should be considered under multidisciplinary monitoring,”…

Liqrev, a new liquid formulation of sildenafil designed for patients who have trouble swallowing tablets, is now available in the U.S., according to an announcement from CMP Pharma, its developer. Liqrev was approved by the U.S. Food and Drug Administration earlier this year as a treatment to improve…

Long COVID syndrome can be common among people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), affecting more than 60% of patients infected with the SARS-CoV-2 virus in a study from Poland. Despite the persistence of COVID-19 symptoms, no change was evident in the patients’ risk of…

Developing chronic thromboembolic pulmonary hypertension (CTEPH) within two years after a venous thromboembolism (VTE), which occurs when a blood clot forms in a vein, nearly doubles the risk of long-term death, according to a large study from Denmark. Researchers also observed that all types of pulmonary hypertension (PH)…

Treatment with intravenous Revatio (sildenafil) can improve oxygen delivery and heart health in some premature babies with pulmonary hypertension, although more than four in 10 patients don’t respond to it. “Our study adds new insights on preterm and [very low birth weight]-infants with sildenafil treatment for primary early PH…

Persistent exercise intolerance in pulmonary arterial hypertension (PAH) patients with treatment-related improvements in blood pressure was associated with impaired muscle function and strength, a study revealed. Because many of the study’s participants have lived with PAH for many years, muscle function may have been compromised, the researchers noted. Interventions…

Treatment with cannabidiol (CBD) for three weeks lowered signs of cardiac fibrosis, or scar tissue build-up, in a rat model of pulmonary hypertension (PH). The findings indicate that CBD may be beneficial for boosting heart function in PH patients via inhibition of certain pro-fibrotic signaling pathways, according to researchers,…

The outcomes used in clinical trials of pulmonary arterial hypertension (PAH) don’t fully reflect the priorities of patients and clinicians, a new study asserts. The study, “‘It’s that invisible illness’: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment,” was published in the journal…

Tenax Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO), indicating that a patent for TNX-103 — oral levosimendan — is to be granted. The patent is expected to cover the use of TNX-103 for treating people with pulmonary hypertension and…